The FDA approved SKINVIVE by JUVEDERM for horizontal neck lines in adults 21 and older on June 16, which makes it the first and only hyaluronic acid injectable cleared specifically for the neck. SKINVIVE is the same intradermal HA microdroplet product (with 0.3% lidocaine) that Allergan brought to market in 2023 for cheek skin smoothness, so this is a second indication on a product many practices already stock rather than a new molecule to learn. The neck has historically been a region most injectors approach carefully, and until now there was no HA option carrying an on-label claim there.

The pivotal data is worth knowing before patients start asking. On the Allergan Transverse Neck Lines Scale, 74.8% of participants reached a clinically significant improvement at one month, and 66% still had that improvement at six months. Severe adverse events showed up in fewer than 5% of the study group (7 of 147), and most events were mild and resolved within about two weeks. That is a useful frame for setting expectations: meaningful but not permanent, with results that drift over the back half of a year.

The practical wrinkle is timing. Allergan expects broad commercial availability later in 2026, so the label exists ahead of the supply, and the gap between approval and stock on your shelf is the window where patients will have read the headline before you can book the treatment. If you take neck consults, it is worth deciding now how you will describe the one-month versus six-month numbers, and whether you fold this into existing JUVEDERM conversations or treat it as its own offering.

Source: AbbVie / Allergan Aesthetics (newsroom) — https://news.abbvie.com/2026-06-16-Allergan-Aesthetics-Receives-U-S-FDA-Approval-for-SKINVIVE-by-JUVEDERM-R-for-the-Improvement-of-Neck-Appearance